TESICO (NCT04843761)
TESICO (Therapeutics for Severely Ill Inpatients with COVID-19) is a master protocol to evaluate the safety and efficacy of investigational agents aimed at improving outcomes for patients with acute respiratory failure related to COVID-19.
SPONSOR: National Institute of Allergy and Infectious Diseases (NIAID)